Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Neurizon-NUZ-001

More Like This

PR Newswire associated0

FDA Lifts Clinical Hold on NUZ-001

PR Newswire associated0

Neurizon Files IND Application to Support HEALEY ALS Platform Trial

PR Newswire associated0

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

PR Newswire associated0

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Business Wire logo

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025

Business Wire logo

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset